Senseonics expects to receive approval for its Eversense 180-day pre-market approval supplement by the end of the year. The company submitted the PMA supplement in October 2020.

The PMA supplement application is being supported by soon-to-be published data from the PROMISE study. The submission was assigned to a lead FDA reviewer on April 15.

If approved, the continuous glucose monitor (CGM) would be approved for 180 days of use, as opposed to the current 90-day indication.